For Immediate Release: February 26, 2020
Press Release — Manhattan. NY. A novel treatment approach for Covid-19 patients has been proposed by Neurologist & Clinical Neurophysiology Dr. Tom Pitts of Hudson Medical Group. Dr. Pitts has expertise in treating immunological diseases which affect the nervous system including Myasthenia gravis, Guillain-Barre Syndrome, and Multiple Sclerosis. His treatment strategies often include modulating specific parts of the immune system which, in these disease states, can cause misdirected and often disproportionately strong attacks against the patient’s own body when a common pathogen such as a viral illness provokes it. It was an understanding of these immunological mechanisms and his management of these complex and rare illnesses which lead to this.
Dr. Pitts has stated that, while the virus is certainly the provocateur, it is the patient’s own disproportionate immune response which often deals the most devastating (and often fatal) damage. A specific part of the immune system, known as the complement, has been shown to cause such damage in other types of coronaviruses. Dr. Pitts uses a special medicine known as Soliris (Eculizumab) to modulate this very specific part of the immune response in multiple disease states. This medication is FDA-approved for multiple rare immunological diseases.
Dr. Pitts suggests that, by modulating this portion of the immune response, mortality can be halted while the patient has time to recover from the virus with supportive medical care. Dr. Pitts suggests that, while the development of an antiviral medication and vaccine would be crucial, halting the body’s own devastating response to the presence of the virus would not only complement those efforts, but it may also stop or lessen mortality in the meantime.
Dr. Pitts has spoken to the FDA and was invited to trial this medication under emergency approval on a case-by-case basis. His proposal is currently being reviewed by the coronavirus workgroup which is a multiagency task force which reviews potential therapies for Covid-19 including the FDA and CDC among others.
Dr. Thomas Pitts is a board-certified Neurology & Clinical Neurophysiologist who received fellowship training at Columbia University Medical Center and who served as Chief Neurology Resident at Wright State University in Dayton Ohio. He is a Gold Humanism Honor Society Inductee and currently serves as the director of Neurology at Hudson Medical & Wellness in Manhattan New York.
For media inquiries, please email email@example.com
Make wellness a part of your health care routine by booking your appointment now. Book Now Same day appointments and procedures available.